Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>ALS Limited plans to raise A$300m through a fully underwritten 5 for 21 accelerated non-renounceable pro rata entitlement offer at a 25% discount to dividend adjusted TERP. We don't see a clear reason for the raise, as the company seems to be plagued more by falling earnings and not by an over leveraged balance sheet. The deal doesn't score well on our framework either.</p><h2>Placement specifics</h2><ul>
<li>Company Name: ALS Ltd</li>
<li>Ticker: ALQ AU Equity</li>
<li>Primary placement -Accelerated non-renounceable pro rata…</li>
</ul>

ALS Limited plans to raise A$300m through a fully underwritten 5 for 21 accelerated non-renounceable pro rata entitlement offer at a 25% discount to dividend adjusted TERP. We don't see a clear reason for the raise, as the company seems to be plagued more by falling earnings and not by an over leveraged balance sheet. The deal doesn't score well on our framework either.Placement specifics
Company Name: ALS Ltd
Ticker: ALQ AU Equity
Primary placement -Accelerated non-renounceable pro rata…


Plain Opportunistic as There Is No Clear Reason for the Equity Issuance